CPI, an independent technology innovation centre and founding member of the UK Government’s High Value Manufacturing Catapult, has today announced a partnership with Perceptive Engineering and FUJIFILM Diosynth Biotechnologies. The companies will develop a data-driven solution to improve efficiencies during downstream biologics processing, reducing the cost of manufacturing life-saving therapies.
Additional data to refine the model will be provided by FUJIFILM Diosynth Biotechnologies. The resins used in the manufacture of biologics are extremely expensive, and failure not only means they must be replaced, but also leads to batches of drugs that do not meet quality standards. The model being developed will enable a much greater understanding of resin failure, and the partners are working to integrate it into CPI’s automated platform to provide real-time insights. This will enable early interventions, while promoting the development of better processes that avoid resin failure altogether.
CPI was instrumental in identifying the funding streams available for the project and writing the initial proposal. Once a working model is developed, CPI will demonstrate proof-of-concept at its National Biologics Manufacturing Centre in Darlington, UK, and it will also investigate the model’s transferability to other platforms.
David Lovett, Managing Director at Perceptive Engineering, said: “By using advances in at-line process analytical technology, the DIICbM project will help to optimise end-to-end manufacturing processes at CPI’s National Biologics Manufacturing Centre. With strategic guidance from world-leading partner FUJIFILM Diosynth Biotechnologies, we are hugely excited by this project.”
To explore optimising end-to-end biologics manufacturing processes contact Perceptive contact us
Throughout development to manufacturing, data is key to enable rapid response to market demand. The knowledge to enable intelligent decisions and the wisdom to optimise the complete product lifecycle is now at your fingertips. The latest release of PerceptiveAPC v8.0 delivers the next
PD2M May 18-20 2021 Virtual This is the place to explore what pharmaceutical manufacturing will look like in 2030, sharing discussions on new ways to develop medicines. How will Industry 4.0 enable us to respond to market demand, delivering flexible, modular manufacturing and bringing
18-19 May 2021 Virtual Perceptive Engineering - an Applied Materials company - is looking forward to participating in the Bionow Pharma Manufacturing Conference 2021. We will be joining AstraZeneca and Bristol Meyers Squibb in session 2, discussing the ‘Digitisation of Pharma
© Perceptive Engineering Ltd 2022